Radiopharm Theranostics Limited
ASX: RAD
Development services growth drives a major revenue surge and narrows losses.
(Source: TradingView) 3-Month Performance Profile of RAD on a DTF compared to S&P/ASX 200 (XJO).
Radiopharm Theranostics delivered a sharp uplift in FY25, with total revenue rising to $3.63 million, a surge of 1,114% year-over-year, driven primarily by expanding developmen
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
